On July 21, CSL Behring and Ferring Pharmaceuticals announced a recall of multiple lots of Stimate (desmopressin) in the United States and in other countries around the world. The recall was prompted by the manufacturer’s discovery of out-of-specification levels of the active ingredient in the marketed product. This announcement has raised many troubling questions among national and international patient organizations and community members. HFA and NHF submitted a letter to CSL Behring and Ferring. Read more.